In FTD and related tauopathies, in vivo findings with 18F-flortaucipir have been mixed, with some suggesting 18F-flortaucipir retention in areas of predicted pathology in CBS and MAPT mutation carriers [19–23]. The gene discussed is MAPT; the disease is frontotemporal dementia.